Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 14, Pages 9718-9734Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00142
Keywords
-
Categories
Funding
- Oxalosis and Hyperoxaluria Foundation [OHF2017]
Ask authors/readers for more resources
This study aimed to find pharmacological chaperones for the treatment of primary hyperoxaluria type I (PH1). The researchers screened and chemically optimized compounds, identifying a promising hit compound and drawing conclusions about the requirements for optimal pharmacological chaperone activity.
Primary hyperoxaluria type I (PH1) is a rare kidney disease due to the deficit of alanine:glyoxylate aminotransferase (AGT), a pyridoxal-5'-phosphate-dependent enzyme responsible for liver glyoxylate detoxification, which in turn prevents oxalate formation and precipitation as kidney stones. Many PH1-associated missense mutations cause AGT misfolding. Therefore, the use of pharmacological chaperones (PCs), small molecules that promote correct folding, represents a useful therapeutic option. To identify ligands acting as PCs for AGT, we first performed a small screening of commercially available compounds. We tested each molecule by a dual approach aimed at defining the inhibition potency on purified proteins and the chaperone activity in cells expressing a misfolded variant associated with PH1. We then performed a chemical optimization campaign and tested the resulting synthetic molecules using the same approach. Overall, the results allowed us to identify a promising hit compound for AGT and draw conclusions about the requirements for optimal PC activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available